Drugs / Allocetra
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06748651 | Dec 2024 → Feb 2026 overdue | temporomandibular joint disorder | Dr. Amit Druyan | Recruiting | No outcome recorded |
| Phase 1 | NCT06522035 | Aug 2024 → Oct 2025 | psoriatic arthritis | Enlivex Therapeutics Ltd. | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06233474 | Jan 2024 → Mar 2026 overdue | osteoarthritis, knee | Enlivex Therapeutics Ltd. | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07580716 | May 2026 → Feb 2027 expected | osteoarthritis, knee | Enlivex Therapeutics Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT06459063 Comparator | Jun 2024 → Sep 2026 overdue | osteoarthritis, hand | Kaplan Medical Center | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 62
| Date | Issuer | Release |
|---|---|---|
| 2026-07-13 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis enlivex.com ↗
Enlivex Ltd. (Nasdaq: ENLV) (“Enlivex” or the “Company”), a quality longevity company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Allocetra™ |
| 2026-06-15 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis enlivex.com ↗
Enlivex Ltd. (Nasdaq: ENLV) (“Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced the issuance of an Australian patent, numbered 2020340629, titled, “THERAPEUTIC APOPTOTIC CELLS FOR TREATMENT OF OSTEOARTHRITIS”. |
| 2026-06-01 | Enlivex Therapeutics Ltd. | Results Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026 enlivex.com ↗
The results demonstrated a clinically meaningful and statistically significant improvement compared to the control placebo arm in reduction of pain and improvement of function in idiopathic age-related osteoarthritis patients ( 60 years), representing more than 50% of the total KOA market. |
| 2026-04-23 | Enlivex Therapeutics Ltd. | Results Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress enlivex.com ↗
The Phase IIa data demonstrated clinically meaningful and statistically significant improvement of the Allocetra™-treated arm in reduction of pain and improvement of function, compared to the control placebo arm, in idiopathic age-related osteoarthritis patients ( 60 years), representing more than 50% of the total KOA market. |
| 2026-04-21 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis enlivex.com ↗ |
| 2026-03-23 | Enlivex Therapeutics Ltd. | Regulatory Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis enlivex.com ↗ |
| 2025-11-24 | Enlivex Therapeutics Ltd. | Results Enlivex Announces Positive 6-Month Topline Data -Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis enlivex.com ↗
At 6 months, Allocetra™ continued to demonstrate substantial and durable reduction in pain and improvement in function across multiple efficacy endpoints evaluated in the same primary age group (60+), as compared to placebo. |
| 2025-10-28 | Enlivex Therapeutics Ltd. | Results Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025 enlivex.com ↗
including clinically meaningful and statistically significant improvement compared to the control placebo arm in reduction of pain and improvement of function |
| 2025-08-18 | Enlivex Therapeutics Ltd. | Results Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis enlivex.com ↗
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive three-month topline data from the Phase IIa stage of ENX-CL-05-001 |
| 2025-03-17 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis enlivex.com ↗
today announced that the China National Intellectual Property Administration (CNIPA) issued a notice of allowance for patent application number 2020800620493. |
| 2025-03-04 | Enlivex Therapeutics Ltd. | Results Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis enlivex.com ↗
Additionally, 83% of treated patients were still considered responders to treatment at six months, which the Company believes highlights the durability and sustained efficacy of Allocetra™ as a potential breakthrough treatment for osteoarthritis. |
| 2025-03-03 | Enlivex Therapeutics Ltd. | Results Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis enlivex.com ↗ |
| 2024-12-11 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis enlivex.com ↗
today announced that the Israeli Ministry of Health authorized the initiation of an investigator-initiated Phase I trial to evaluate the safety, tolerability and initial efficacy of Allocetra™ for injection into the temporomandibular joint (TMJ) in patients suffering from TMJ osteoarthritis. |
| 2024-12-03 | Enlivex Therapeutics Ltd. | Results Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis enlivex.com ↗
The interim efficacy results are highly positive, statistically significant (p-value < 0.0007, n=12), and show marked improvements in all key efficacy endpoints, including reduction of pain and an improvement in functionality, compared to baseline. |
| 2024-09-26 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis enlivex.com ↗
Nes-Ziona, Israel, Sept. 26, 2024 — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Danish Medicines Agency authorized the initiation of the Phase II stage of the Company’s multi-country Phase I/II trial in moderate and severe knee osteoarthritis. |
| 2024-09-24 | Enlivex Therapeutics Ltd. | Results Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis enlivex.com ↗
Patients in the Phase I safety run-in were treated with three sequential injections of Allocetra™ at escalating doses, and no serious adverse reactions were reported during or following the treatment. |
| 2024-07-23 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis enlivex.com ↗
today announced that the Israeli Ministry of Health has authorized the initiation of a Phase I clinical trial to evaluate the safety and tolerability of Allocetra™ following injection into an affected joint in patients with psoriatic arthritis. |
| 2024-06-17 | Enlivex Therapeutics Ltd. | Results Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis enlivex.com ↗
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today released a positive interim data readout from a Phase I/II investigator-initiated clinical trial of AllocetraTM in patients with end-stage knee osteoarthritis who had been indicated for knee replacement surgery. |
| 2024-06-03 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis enlivex.com ↗ |
| 2024-04-16 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis enlivex.com ↗
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Danish Medicines Agency (DKMA) authorized the expansion into Denmark of the Company’s multi-country, randomized, controlled Phase I/II trial evaluating AllocetraTM in up to 160 patients with moderate to severe knee osteoarthritis. |
| 2024-04-11 | Enlivex Therapeutics Ltd. | Results Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis enlivex.com ↗
Stand-alone analysis of the Allocetra™-treated patients, of which 78% had septic shock and 65% had invasive ventilation at screening, demonstrated substantial reductions in SOFA scores and 65% reduction in overall mortality rate as compared with expected mortality2. |
| 2024-02-26 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis enlivex.com ↗
In January, the Israeli Ministry of Health (IMOH) authorized the initiation of a new trial for AllocetraTM, a groundbreaking cell therapy that could help treat osteoarthritis patients. |
| 2024-01-17 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis enlivex.com ↗ |
| 2023-08-02 | Enlivex Therapeutics Ltd. | Results Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19 enlivex.com ↗
This study had excellent results, leading to early discharge from a hospital of 17 out of 19 patients with ARDS along with resolution of the cytokine storms observed in these patients. |
| 2023-05-08 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy enlivex.com ↗
today announced the issuance of a European patent, numbered 3865189, entitled, “Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment.” |
| 2023-04-19 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra™ in Patients Receiving CAR T-Cell Therapy enlivex.com ↗ |
| 2023-03-20 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers enlivex.com ↗
The Israeli Ministry of Health (IMOH) also reviewed the interim data and provided regulatory clearance to continue the study and open the study’s next cohort. |
| 2023-02-23 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Clearance From Spanish Agency of Medicines and Medical Devices For Treatment of Patients with Advanced Solid Malignancies in the Ongoing Allocetra Phase I/II Clinical Trial enlivex.com ↗
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has authorized the expansion of the Company’s Phase I/II of AllocetraTM in patients with advanced solid malignancies. |
| 2023-01-25 | Enlivex Therapeutics Ltd. | Results Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors enlivex.com ↗
There were no mortalities nor DSMB-identified safety signals in the first cohort, and the DSMB recommended that the study continue as designed. |
| 2023-01-04 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Authorizations from French and Belgian Regulatory Agencies To Expand Its Phase II Sepsis Clinical Trial Into France and Belgium enlivex.com ↗
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the French Agency for Food, Environmental and Occupational Health and Safety (ANSES) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have cleared the amended protocol of the Company’s Phase II trial evaluating Allocetra™ in patients with sepsis. |
| 2022-11-28 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies enlivex.com ↗ |
| 2022-09-12 | Enlivex Therapeutics Ltd. | Results Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022 enlivex.com ↗ |
| 2022-08-29 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Notice of Allowance for Japanese Patent Application Covering Allocetra Derived from Pooled Donor Cells enlivex.com ↗
today announced that the Japanese Patent Office issued a Notice of Allowance for patent application number 2020-198242. |
| 2022-08-24 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Announces Regulatory Clearance in Multiple Countries for Integration of Frozen Allocetra Formulation and Expansion of Patient Population in its Sepsis Phase II Clinical Trial enlivex.com ↗
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that regulatory authorities in Israel, Spain, and Greece have cleared amendments to the protocol of the Company’s Phase II trial evaluating Allocetra™ in patients with sepsis. |
| 2022-08-17 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Israeli Ministry of Health Approval for the Initiation of a Phase I/II Trial Evaluating Allocetra™ Alone and in Combination with a PD1 Checkpoint Inhibitor in Patients with Advanced Solid Tumors enlivex.com ↗
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Israeli Ministry of Health (MOH) authorized the initiation of a company-sponsored Phase I/II clinical trial designed to evaluate the safety, tolerability and preliminary efficacy of Allocetra™ alone, and in combination with a PD1 checkpoint inhibitor, in patients with advanced solid tumors. |
| 2022-08-03 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Sepsis with Allocetra™ enlivex.com ↗ |
| 2022-06-06 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers enlivex.com ↗
today announced that the Israeli Ministry of Health (MOH) authorized the initiation of a company-sponsored Phase I/II clinical trial evaluating Allocetra™ combined with chemotherapy in patients with peritoneal metastases arising from solid cancer. |
| 2022-05-31 | Enlivex Therapeutics Ltd. | Results Enlivex Announces New Preclinical Data in Ovarian Cancer Showing a Substantial Survival Benefit when Allocetra is Combined with PD-1 Checkpoint Inhibition at the American Society of Clinical Oncology (ASCO) Annual Meeting enlivex.com ↗
The study showed substantial and statistically significant improvements in survival benefit, survival duration and tumor burden reduction when Allocetra™ was combined with an anti-PD1 checkpoint inhibitor. |
| 2022-05-09 | Enlivex Therapeutics Ltd. | Results Enlivex Presented Substantial Survival Benefit of Allocetra in Combination with Immune Checkpoint Inhibitor in Mesothelioma Cancer Study at the International Society for Cell and Gene Therapy Annual 2022 Meeting enlivex.com ↗
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, announced the poster presentation of a substantial survival benefit of AllocetraTM combined with immune checkpoint inhibition in a preclinical mesothelioma study at the International Society of Cell and Gene Therapy Annual 2022 Meeting. |
| 2022-05-05 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra enlivex.com ↗
today announced the issuance of U.S. Patent Nos. 11,304,976 and 11,318,163. |
| 2021-12-07 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece enlivex.com ↗ |
| 2021-12-06 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Notice of Allowance for U.S. Patent Application Covering the Treatment of Sepsis Patients with Allocetra enlivex.com ↗
today announced that the U.S. Patent and Trademark Office issued a notice of allowance for a new patent application (number 16/194,417) covering AllocetraTM, the Company’s immunotherapy product candidate. |
| 2021-11-04 | Enlivex Therapeutics Ltd. | Regulatory Spanish Regulator Grants Enlivex Authorization To Expand Its Sepsis Phase II into Spain enlivex.com ↗
today announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has authorized the expansion to clinical sites in Spain of the Company’s multi-center, placebo-controlled, randomized, dose-finding, Phase II trial of AllocetraTM in patients with pneumonia-associated sepsis. |
| 2021-10-04 | Enlivex Therapeutics Ltd. | Results Enlivex Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data from Phase Ib Trial Evaluating Allocetra in Patients with Sepsis enlivex.com ↗
Data published in Frontiers in Immunology show a robust safety profile and substantial improvements in state of organ failure, duration of ICU stay, and mortality in 10 Allocetra-treated severe sepsis patients vs. matched historical controls |
| 2021-02-03 | Enlivex Therapeutics Ltd. | Results Enlivex Reports Positive Top-Line Results from Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients and Provides a Program Update enlivex.com ↗
Based on the positive safety and efficacy results from the Phase II trial and in consultation with the trial’s principal investigator, the Company has completed the Phase II trial early after enrolling sixteen, rather than twenty-four, patients. |
| 2020-12-03 | Enlivex Therapeutics Ltd. | Results Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients enlivex.com ↗ |
| 2020-11-18 | Enlivex Therapeutics Ltd. | Results Enlivex Reports Positive Two-Year Clinical Outcome For A Hospitalized Patient with Erosive Osteoarthritis Treated with Allocetra enlivex.com ↗ |
| 2020-11-05 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Receives Notice of Allowance for U.S. Patent Application Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, and Ulcerative Colitis with Allocetra Immunotherapy enlivex.com ↗ |
| 2020-11-03 | Enlivex Therapeutics Ltd. | Regulatory Enlivex: Israeli Ministry of Health Authorizes Initiation of Phase IIb Clinical Trial Evaluating Safety and Efficacy of Allocetra in Sepsis Patients enlivex.com ↗
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the Israeli Ministry of Health authorized the initiation of a proposed Company-sponsored Phase IIb clinical trial evaluating Allocetra™, in sepsis patients. |
| 2020-10-13 | Enlivex Therapeutics Ltd. | Regulatory Enlivex: After Expedited Review, Israeli Ministry of Health Authorizes Initiation of Phase II Clinical Trial Evaluating Allocetra in COVID-19 Severe and Critical Patients enlivex.com ↗
Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the Israeli Ministry of Health authorized the initiation of a proposed investigator-initiated Phase II clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients. |
| 2020-05-28 | Enlivex Therapeutics Ltd. | Results Enlivex Presents New Clinical Data Demonstrating Early Resolution of Cytokine Storms in Sepsis Patients Treated with Allocetra at the International Society for Cellular Therapy 2020 Paris Virtual Annual Meeting enlivex.com ↗
The presentation will include new exploratory endpoint analyses that demonstrated the potential of AllocetraTM to resolve cytokine storms with heterogenous underlying pathologies, as well as previously disclosed safety and efficacy data. |
| 2020-03-18 | Enlivex Therapeutics Ltd. | Results Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis enlivex.com ↗
Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced positive final safety and efficacy data from the Company’s completed Phase Ib clinical trial in patients with severe sepsis. |
| 2020-03-03 | Enlivex Therapeutics Ltd. | Regulatory Enlivex Therapeutics Confirms Public Statements Made by the Head of Israel Economic and Commercial Mission to South Korea enlivex.com ↗ |
| 2020-02-20 | Enlivex Therapeutics Ltd. | Results Data On Enlivex’s Allocetra-OTS Immunotherapy for Peritoneal Solid Tumors and for Prevention of GvHD Selected for Presentation at the Transplantation & Cellular Therapy Meetings Conference (TCT) in Orlando, Florida enlivex.com ↗
Results from preclinical and clinical studiesy suggested that a single infusion of donor early apoptotic cells (Allocetra) as prophylaxis for GvHD in myeloablative HSCT is safe and potentially effective |
| 2019-11-04 | Enlivex Therapeutics Ltd. | Results Enlivex Therapeutics Announces Positive Interim Safety and Efficacy Data From Ongoing Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis enlivex.com ↗
None (0 of 6) of the OTS Allocetra -treated patients died during this period, compared to 11 of 37 (29%) in the matched control group who died during this period. |
| 2019-10-10 | Enlivex Therapeutics Ltd. | Results Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected For Presentation At The XVIIIth Congress Of the European and Int’l Shock Societies enlivex.com ↗
The data showed ten-fold (10x) increased survival for study subjects who were treated with Allocetra-OTS therapy and antibiotics and fluids, as compared to subjects treated solely with antibiotics and fluids. |
| 2019-10-08 | Enlivex Therapeutics Ltd. | Regulatory European Patent Office Grants New Patent Covering Enlivex’s Allocetra™ Immunotherapy Treatment enlivex.com ↗ |
| 2019-10-07 | Enlivex Therapeutics Ltd. | Results Data On Combination Of Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Selected For Presentation At The European Molecular Biology Organization’s 2019 Cell Death in Immunity and Inflammation Workshop enlivex.com ↗
Enlivex’s data showed significantly increased duration of survival and overall survival for study subjects who were treated with the combination therapy, as compared to stand-alone solid tumor CAR-T therapy. |
| 2019-08-19 | Enlivex Therapeutics Ltd. | Results Enlivex Therapeutics Announces Positive Outcome From Safety Committee’s Review Of Six Patients With Severe Sepsis Patients; Enrollment Of Last Study Cohort Approved enlivex.com ↗
Following this recommendation, the regulatory authorities approved the continued enrollment in the last cohort in the study, which will include four additional patients. |
| 2019-06-06 | Enlivex Therapeutics Ltd. | Results Enlivex Therapeutics Provides Clinical Update on Positive Safety Profile of Its Off-The-Shelf Cell Therapy Product in First Three Severe Sepsis Patients enlivex.com ↗
All three patients tolerated the infusion without serious adverse events. |
| 2018-11-24 | Enlivex Therapeutics Ltd. | Regulatory New patent covering Enlivex's Allocetra™ immunotherapy treatment was allowed in Australia enlivex.com ↗
Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Australian Patent Office (IP Australia) issued a notice of allowance for a patent application covering ALLOCETRA™, the company’s immunotherapy product. |
| 2018-09-18 | Enlivex Therapeutics Ltd. | Regulatory New patent covering Enlivex's Allocetra™ immunotherapy treatment was granted by the U.S. patent office enlivex.com ↗
Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the U.S. Patent Office (USPTO) issued a new patent application covering ALLOCETRA™, the company’s immunotherapy product. |
All press releases naming this drug 116 releases
| Date | Issuer | Release |
|---|---|---|
| Show all 116 releases opens the full record — a long page | ||
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allocetra | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06233474 ↗ |
| Known as | Allocetra-OTS | “Allocetra-OTS is a cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear cells, induced to an apoptotic stable state” NCT06233474 ↗ |
| Modality | Cell therapy | “Allocetra-OTS is a cell-based therapy” NCT06233474 ↗ |
| Route | Other | “Three intra-articular injections of Allocetra at a selected dose, into the index knee.” NCT06233474 ↗ |